{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:28:57Z","timestamp":1788557337556,"version":"build-2803163510"},"reference-count":24,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T00:00:00Z","timestamp":1701561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Experimental Optometry"],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.1080\/08164622.2023.2279189","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:24:16Z","timestamp":1701660256000},"page":"665-672","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance"],"prefix":"10.1080","volume":"107","author":[{"suffix":"IV","given":"George O","family":"Waring","sequence":"first","affiliation":[{"name":"Waring Vision Institute, Mt Pleasant, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mile","family":"Brujic","sequence":"additional","affiliation":[{"name":"Premier Vision Group, Bowling Green, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-2428","authenticated-orcid":false,"given":"Selina","family":"McGee","sequence":"additional","affiliation":[{"name":"BeSpoke Vision, Edmond, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-5573","authenticated-orcid":false,"given":"J Morgan","family":"Micheletti","sequence":"additional","affiliation":[{"name":"Berkeley Eye Center, Sugar Land, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhao","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Schachter","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Liu","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Safyan","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,3]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051385"},{"key":"e_1_3_7_3_1","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Presbyopia: overview. [accessed 2023 Aug 14]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK423833\/?report=reader#_NBK423833_pubdet."},{"key":"e_1_3_7_4_1","unstructured":"American Optometric Association. Optometric clinical practice guideline - care of the patient with presbyopia. [accessed 2023 Aug 14]. https:\/\/www.sdeyes.org\/docs\/CPG-17.pdf."},{"key":"e_1_3_7_5_1","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). How can presbyopia be corrected? [accessed 2023 Aug 14]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK423827\/?report=reader."},{"key":"e_1_3_7_6_1","unstructured":"United Nations Department of Economic and Social Affairs. World population ageing 2020 highlights. [accessed 2023 Aug 14]. https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2020\/Sep\/un_pop_2020_pf_ageing_10_key_messages.pdf."},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.013"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.17925\/USOR.2022.16.2.54"},{"key":"e_1_3_7_9_1","unstructured":"Allergan. VUITYTM (pilocarpine hydrochloride ophthalmic solution) 1.25% for topical ophthalmic use [prescribing info]. [accessed 2023 Aug 14]. https:\/\/www.rxabbvie.com\/pdf\/vuity_pi.pdf."},{"key":"e_1_3_7_10_1","unstructured":"AbbVie. VUITY\u2122 (pilocarpine HCI ophthalmic solution) 1.25% the first and only FDA-approved eye drop to treat age-related blurry near vision (presbyopia) is now available. [accessed 2023 Aug 14]. https:\/\/news.abbvie.com\/news\/press-releases\/vuity-pilocarpine-hci-ophthalmic-solution-125-first-and-only-fda-approved-eye-drop-to-treat-age-related-blurry-near-vision-presbyopia-is-now-available.htm."},{"key":"e_1_3_7_11_1","unstructured":"National Library of Medicine. ClinicalTrials.Gov glossary terms. [accessed 2023 Jun 21]. https:\/\/clinicaltrials.gov\/study-basics\/glossary."},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0059"},{"key":"e_1_3_7_13_1","unstructured":"Alcon Laboratories. Isopto\u00ae carpine (pilocarpine hydrochloride ophthalmic solution) 1% 2% and 4% [prescribing info]. [accessed 2023 Aug 14]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/200890s001lbl.pdf."},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1518\/0018720024497664"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13369"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3181d95b0d"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2009.06.017"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/opx.0000000000001466"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v17i1.10166"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2020.1833347"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2016.12.16"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5154"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0b013e3181a1435e"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.08.021"},{"key":"e_1_3_7_26_1","volume-title":"American Academy of Optometry (AAOpt) 2022 Annual Meeting","author":"Johnston J","year":"2022","unstructured":"Johnston J, Feulner L, Davidson J et al. Pilocarpine HCl ophthalmic solution 1.25% in moderate presbyopia: a post hoc analysis of the GEMINI phase 3 trials. American Academy of Optometry (AAOpt) 2022 Annual Meeting; 2022; San Diego, CA, USA."}],"container-title":["Clinical and Experimental Optometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08164622.2023.2279189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T02:48:25Z","timestamp":1727232505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08164622.2023.2279189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,3]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,17]]}},"alternative-id":["10.1080\/08164622.2023.2279189"],"URL":"https:\/\/doi.org\/10.1080\/08164622.2023.2279189","relation":{},"ISSN":["0816-4622","1444-0938"],"issn-type":[{"value":"0816-4622","type":"print"},{"value":"1444-0938","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tceo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tceo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}